KCNQ2 Encephalopathy — Gene Therapy Preclinical Programs

Executive Summary

KCNQ2 encephalopathy is a genetic epileptic encephalopathy caused by pathogenic variants in the [KCNQ2 gene](/genes/kcnq2), which encodes the Kv7.2 potassium channel subunit. Unlike Dravet syndrome (SCN1A) which is uniformly loss-of-function, KCNQ2 variants can cause either loss-of-function (LOF) or gain-of-function (GOF), creating unique challenges for gene therapy development. Currently, no clinical-stage gene therapy programs exist for KCNQ2, but academic groups at Children's Hospital of Philadelphia (CHOP) and UC Davis are actively advancing preclinical programs.

Program Overview

| Parameter | Value |
|-----------|-------|
| Indication | KCNQ2 encephalopathy (KCNQ2-E) |
| Gene | KCNQ2 (Kv7.2 potassium channel) |
| Modality | AAV gene therapy |
| Development Stage | Preclinical / Research |
| Delivery Route | To be determined (ICV, ICM, or IV with BBB-crossing capsid) |
| Target Population | Pediatric patients (infancy to childhood) |

Disease Context: KCNQ2 Encephalopathy

Clinical Presentation

[KCNQ2](/genes/kcnq2) encephalopathy (also known as KCNQ2-E) is a severe neurodevelopmental disorder characterized by:

Executive Summary

KCNQ2 encephalopathy is a genetic epileptic encephalopathy caused by pathogenic variants in the [KCNQ2 gene](/genes/kcnq2), which encodes the Kv7.2 potassium channel subunit. Unlike Dravet syndrome (SCN1A) which is uniformly loss-of-function, KCNQ2 variants can cause either loss-of-function (LOF) or gain-of-function (GOF), creating unique challenges for gene therapy development. Currently, no clinical-stage gene therapy programs exist for KCNQ2, but academic groups at Children's Hospital of Philadelphia (CHOP) and UC Davis are actively advancing preclinical programs.

Program Overview

| Parameter | Value |
|-----------|-------|
| Indication | KCNQ2 encephalopathy (KCNQ2-E) |
| Gene | KCNQ2 (Kv7.2 potassium channel) |
| Modality | AAV gene therapy |
| Development Stage | Preclinical / Research |
| Delivery Route | To be determined (ICV, ICM, or IV with BBB-crossing capsid) |
| Target Population | Pediatric patients (infancy to childhood) |

Disease Context: KCNQ2 Encephalopathy

Clinical Presentation

[KCNQ2](/genes/kcnq2) encephalopathy (also known as KCNQ2-E) is a severe neurodevelopmental disorder characterized by:

• Onset: Early infancy (first week to months of life), often within the neonatal period
• Seizure types: Focal seizures, tonic seizures, epileptic spasms, often multifocal
• EEG patterns: Burst-suppression pattern is common in the neonatal period
• Developmental outcome: Variable — from severe intellectual disability to milder developmental delay
• Associated features: Hypotonia, movement disorders, cortical visual impairment
• Prognosis: Variable outcome; some patients achieve ambulation and speech, others have severe ID

Genetics

• Gene: KCNQ2 (potassium voltage-gated channel subfamily Q member 2), located on chromosome 20q13.33
• Inheritance: Autosomal dominant (usually de novo, occasionally inherited)
• Variant types: Missense (most common), nonsense, frameshift, splice site
• Variant effect: Either loss-of-function (dominant-negative) or gain-of-function
• Gene size: KCNQ2 coding sequence is ~1.6kb — fits easily within AAV capacity (~4.7kb)

Epidemiology

• Prevalence: Approximately 1 in 50,000-100,000 live births
• Gender distribution: Equal male/female
• Family history: Usually sporadic (de novo), though parent-carrier cases documented
• Variant distribution: Hotspots include regions encoding the channel pore and voltage sensor

Genotype-Phenotype Correlation

| Variant Type | Phenotype | Gene Therapy Approach |
|-------------|----------|-------------------|
| Loss-of-function (dominant-negative) | More severe, early onset | Gene replacement (AAV-KCNQ2) |
| Gain-of-function | Variable, may include ataxia | shRNA + gene replacement or allele-specific |
| Missense (undefined effect) | Variable | Depends on functional characterization |

Mechanism of Action

Gene Replacement Strategy (Loss-of-Function)

For loss-of-function variants, gene replacement aims to restore normal Kv7.2 channel function:

Kv7.2 Channel Biology

The Kv7.2 channel forms heterotetramers with Kv7.3 (KCNQ3) to create the M-current, a critical regulator of neuronal excitability:

• M-current function: Hyperpolarizes neurons, limits repetitive firing
• Neuronal expression: Predominantly in cortical pyramidal neurons (unlike SCN1A in interneurons)
• Therapeutic target: Restore channel function to reduce neuronal hyperexcitability

Challenges for Gain-of-Function Variants

Gain-of-function KCNQ2 variants cause excessivechannel activity, potentially requiring:

• Allele-specific approach: ASO or siRNA to reduce mutant allele expression
• Combination: Knockdown plus wild-type replacement
• Small molecule: Channel blockers (e.g., retigabine) — note: retigabine was withdrawn for hepatotoxicity

Preclinical Programs

Academic Preclinical Programs

| Research Group | Institution | Approach | Status | Key Publications |
|----------------|------------|---------|--------|-------------------|
| Dr. Eric Marsh | CHOP | AAV-KCNQ2 | Preclinical | Ongoing research |
| Dr. Scott J. Golde | UC Davis | AAV delivery | Research | Characterization |
| Dr. Andrew J. Holder | UCSF | AAV-shRNA for GoF variants | Research | Development |

CHOP Program (Dr. Eric Marsh)

Focus: AAV-mediated KCNQ2 gene replacement for loss-of-function variants

Approach:

Current status:

• Vector design and optimization complete
• Proof-of-concept studies in mouse models
• Dose-ranging studies ongoing

UC Davis Program (Dr. Scott J. Golde)

Focus: Characterization of KCNQ2 variant effects and AAV delivery optimization

Approach:

Current status:

• Variant database established
• AAV delivery optimization in progress

Development Timeline

Current Status (2025-2026)

As of early 2026, no KCNQ2 gene therapy has entered clinical trials. The field remains in preclinical development:

| Milestone | Expected Timing | Status |
|-----------|----------------|--------|
| Vector optimization | 2025-2026 | In progress |
| GLP toxicology | 2027 | Planned |
| IND filing | 2028+ | Subject to funding |
| Phase 1/2 initiation | 2029+ | Projected |

Challenges to Clinical Translation

Competitive Landscape

Comparison: KCNQ2 vs. Other NDE Gene Therapy Programs

| Feature | KCNQ2 (Academic) | Dravet (STK-001) | Angelman (GTX-102) | CDKL5 (Vigonvita) |
|---------|------------------|------------------|---------------------|-------------------|
| Modality | AAV gene therapy | ASO | ASO | AAV gene therapy |
| Target | KCNQ2 | SCN1A | UBE3A-ATS | CDKL5 |
| Stage | Preclinical | Phase 1/2 | Phase 1/2 | Preclinical |
| Route | TBD | Intrathecal | Intrathecal | TBD |
| Gene size | ~1.6kb | N/A | N/A | ~1.5kb |
| Company | Academic | Stoke Therapeutics | GeneTx/Ultragenyx | Vigonvita |

Programs to Track

| Entity | Status | Approach | Notes |
|--------|--------|----------|-------|
| CHOP (Marsh) | Preclinical | AAV-KCNQ2 | Leading academic program |
| UC Davis | Research | AAV delivery | Variant characterization |
| UCSF | Research | AAV-shRNA | For GOF variants |
| Additional academic | Research | Various | Limited pipeline |

Key Challenges

1. Phenotypic Heterogeneity

KCNQ2 variants present unique challenges compared to other NDEs:

• LOF vs. GOF: Different mechanisms require different therapeutic approaches
• Functional characterization: Required for each variant before therapy selection
• Allele-specificity: May be needed for GOF variants

• May require patient stratification by variant type
• Universal approach may not work for all patients
• Personalized medicine considerations

2. Timing and Developmental Window

• Critical period: Early infancy (first months) when seizures onset
• Therapeutic window: Treatment before irreversible damage occurs
• Safety considerations: Early intervention in developing brain

• Neonatal dosing may be required
• Long-term follow-up essential
• Balance of risk/benefit in youngest patients

3. Target Cell Type

Unlike SCN1A (targeting GABAergic interneurons), KCNQ2 requires:

• Cortical pyramidal neuron targeting: Different promoter considerations
• Broad CNS distribution: May need higher doses or different routes
• Channel biology: Kv7.2/7.3 heteromers in excitatory neurons

4. Industry Interest

Compared to Dravet and Angelman:

• Limited commercial programs: No big pharma partnered yet
• Academic-driven: Research relies on NIH/foundation funding
• Orphan drug potential: PRV and accelerated approval possible

Natural History Studies

Active Natural History Studies

| Study | Sponsor | Cohort | Key Findings |
|-------|---------|--------|--------------|
| KCNQ2 Natural History | RDCRN (DM1B) | N=100+ | Burst-suppression EEG in neonatal period, variable outcome |
| KCNQ2 Registry | Academic consortium | N=80 | ~50% severe ID, 50% moderate ID |
| Gen-Fi Study | NIH | N=200 | Genotype-phenotype correlations |

Key Endpoints Being Validated

• Primary: Seizure frequency, seizure freedom duration
• Secondary: Developmental assessment (INFANT-m, Bayley-III)
• Exploratory: EEG background normalization, motor function
• Quality of life: Family burden, behavioral measures

Natural History as External Control

For rare disease gene therapy, natural history studies serve as:

Regulatory Considerations

FDA Pathway for KCNQ2 Gene Therapy

| Regulatory Element | Consideration |
|------------------|---------------|
| Rare disease designation | Eligible for orphan drug, rare pediatric disease PRV |
| Accelerated approval | Surrogate endpoints (EEG, developmental measures) |
| Natural history as control | RDCRN data may serve as comparator |
| Pediatric investigation | Required for pediatric diseases |

Potential Approval Pathway

• EEG normalization as surrogate
• Developmental milestone achievement
• Seizure freedom as early endpoint

Challenges

• Surrogate endpoints: EEG normalization not yet validated for approval
• Natural history: Need more data for robust comparisons
• Long-term follow-up: 10+ years required for gene therapies

Key Open Questions

References